Anumana Entered into a Multi-Year Strategic Collaboration with Novartis to Develop ECG AI Algorithms for the Detection of Heart Disease
Related Articles
Anumana earns first full FDA clearance for AI to detect low ejection fraction
Fierce Biotech: Two years after its launch as a joint venture between the Mayo Clinic and Nference to develop artificial intelligence algorithms capable of pulling out new insights from routine…October 05, 2023
Anumana’s ECG Pulmonary Hypertension AI Algorithm Gains Breakthrough Status
Medical Product Outsourcing: Artificial intelligence (AI)-driven healthtech company, Anumana has received U.S. Food and Drug Administration (FDA) Breakthrough Device Designation for its AI-enhanced, ECG-based pulmonary hypertension (PH) early detection algorithm.…May 23, 2022
Anumana Appoints Harry S. Palmin as CFO
Anumana Appoints Harry S. Palmin as CFOCAMBRIDGE, Mass. – May 14, 2024 Anumana, a leading AI-driven health technology company and portfolio company of nference, today announced the appointment of Harry…May 14, 2024
Anumana Appoints Maulik Nanavaty as CEO
Anumana Appoints Maulik Nanavaty as CEOCAMBRIDGE, Mass. – October 19, 2023 – Anumana, Inc., a leading AI-driven health technology company and portfolio company of nference, today announced that Maulik Nanavaty…October 19, 2023